Viracta Therapeutics

About:

Viracta Therapeutics is a precision oncology company focused on new treatment of virus-associated malignancies.

Website: https://www.viracta.com

Twitter/X: ViractaT

Top Investors: Samsara BioCapital, Biotechnology Value Fund, Silicon Valley Bank, Taiwania Capital Management Corporation, Janus Henderson Investors

Description:

Viracta is a precision oncology company targeting virus-associated malignancies. Viracta's proprietary investigational drug, nanatinostat, is currently being evaluated in combination with the antiviral agent valganciclovir as an oral combination therapy in a Phase 2 clinical trial for EBV-positive lymphoma. Viracta is pursuing application of this inducible synthetic lethality approach in other EBV-associated malignancies, such as nasopharyngeal carcinoma, gastric carcinoma, and other virus-related cancers.